UNSPSC 51263143: Acebutolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H28N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B025Y34C54, chemically known as m&b 17,803a but more generally known as acebutolol hydrochloride, which bears US NIH Compound Identifier 36816. The base preparation, Acebutolol, also comes in forms base, azide, and methylboronate. European Medicines Agency schedules Acebutolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00240MIG.

UNSPSC 51263143 Acebutolol hydrochloride is a Commodity code that in recent state and local procurement activity tracks pharmaceutical products and drug-related supplies, though the recent opportunities tagged to this code show minimal direct alignment with the nominal pharmaceutical active ingredient. Seminole County, Florida and the Texas Health and Human Services Commission have posted solicitations tagged to this code, but neither procurement is buying acebutolol hydrochloride specifically — Seminole County is purchasing naloxone and drug deactivation systems, and Texas HHS is gathering market intelligence on direct-to-manufacturer prescription fulfillment models. The mismatch suggests either tagging inconsistency on the issuing-body side or that this code functions as a catch-all for pharmaceutical-adjacent procurement at the state and local level. Issuing bodies include county health departments and state health and human services agencies; the recent record does not show school districts, transit authorities, or other municipal procurement offices using this code.

The geographic spread reflected in recent opportunities spans Florida and Texas, with no other states represented in the current activity block. The two representative recent opportunities are Seminole County's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; and the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, also due April 3, 2026, which is exploratory market research into direct-to-manufacturer prescription contracting rather than a binding competitive solicitation. The Seminole County opportunity carries a three-month probationary termination clause and potential FEMA funding with associated federal compliance requirements. This code shows sparse recent activity with weak alignment between the nominal commodity and the work actually being sought.